Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.

8 Mar 2010

Positive data from Argos Therapeutics' AGS-003 Phase 2 trial for mRCC

Argos Therapeutics today announced the presentation of positive data from a Phase 2 trial that evaluated the safety, clinical response and immune response of AGS-003 treatment in newly diagnosed patients with metastatic renal cell carcinoma (mRCC). The data were discussed March 7 in a poster presentation at the ASCO Genitourinary Cancers Symposium.

8 Mar 2010

Men employed in occupations with potential exposure to sunlight have reduced risk of kidney cancer

According to a new study, men employed in occupations with potential exposure to high levels of sunlight have a reduced risk of kidney cancer compared with men who were less likely to be exposed to sunlight at work.

8 Mar 2010

Liver transplantation specialists form guidelines for allocation of organs for patients with HCC

Liver transplantation specialists recently convened to address U.S. guidelines for allocation of organs for patients with hepatocellular carcinoma (HCC, liver cancer). Representatives from more than 130 U.S. transplant centers were invited to the conference and participants included 180 leaders in liver transplantation (LT) from the 50 most active centers.

5 Mar 2010

OSCC cells express VEGFR1, VEGFR2 and serve as targets and effectors for VEGF: Study

Today, during the 39th Annual Meeting of the American Association for Dental Research, convening at the Walter E. Washington Convention Center in Washington, DC, lead researcher M. Tong, The Ohio State University, will present a poster of a study titled "Epithelial-to-Endothelial Transition: An Epithelial Phenotypic Modulation Facilitating Oral-Squamous-Cell Carcinoma Progression."

5 Mar 2010

bioTheranostics launches CancerTYPE ID database and KRAS mutational testing

bioTheranostics, a bioMerieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announces the launch of an expanded tumor-type database for its flagship product, CancerTYPE ID®, and the launch of KRAS mutational testing.

5 Mar 2010

Study shows link between Vitamin D levels and basal cell carcinoma

A Henry Ford Hospital study has shown a link between Vitamin D levels and basal cell carcinoma, a finding that could lead researchers to better understand the development of the most common form of skin cancer.

5 Mar 2010

PINC trial to test anti-malarial drug in women with DCIS

Can a drug that has been used to treat malaria for years possibly be used to treat breast cancer before it becomes invasive? That's what researchers at George Mason University's Center for Applied Proteomics and Molecular Medicine (CAPMM) and Inova Breast Care Institute (IBCI) are trying to prove.

3 Mar 2010

ArQule reports net loss of $36,136,000 for 2009

ArQule, Inc. today announced its financial results for the year and for the fourth quarter ended December 31, 2009.

2 Mar 2010

Celsion to commence Phase II Study of ThermoDox and RFA for CRLM

Celsion Corporation today announced that it will initiate a Randomized Phase II Study of Lyso-Thermosensitive Liposomal Doxorubicin (ThermoDox®) and Radiofrequency Ablation (RFA) for Colorectal Liver Metastases (CRLM). Dr. Steven K. Libutti, Professor and Vice Chairman, Department of Surgery and Director of the Montefiore-Einstein Center for Cancer Care and Albert Einstein College of Medicine in New York City, will serve as Principal Investigator for the study.

2 Mar 2010

SUVmax in head and neck squamous cell carcinoma patients predict overall survival

The maximal standardized uptake value (called SUVmax) measured from FDG PET readings taken from the primary tumor in head and neck squamous cell carcinoma patients before treatment is a strong predictor of disease-specific survival, overall survival and disease-free survival, while pretreatment SUVmax for lymphodenopathy is strongly associated with distant metastasis, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

1 Mar 2010

Study shows ghrelin prevents acute liver damage, reduces oxidative stress and inflammation

Spanish researchers determined that rats treated with recombinant ghrelin displayed a reduction in liver fibrosis. Ghrelin, a stomach hormone, reduced the amount of fibrogenic cells by 25% in the treated rodents. Research further showed ghrelin prevented acute liver damage and reduced oxidative stress and inflammation in the animal models.

1 Mar 2010

Widely used biomarkers in early detection of liver cancer are not ideal: Study

Widely used biomarkers are not optimal in early detection of liver cancer, the third most common cause of cancer-related death worldwide, according to a new study published in this month's Gastroenterology.

26 Feb 2010

Combining DCP and AFP biomarkers may improve early detection of liver cancer

While biomarkers are needed to complement ultrasound in the early detection of hepatocellular carcinoma (HCC; liver cancer), neither des-gamma-carboxy prothrombin (DCP) nor the most widely used biomarker, alpha fetoprotein (AFP), is optimal, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

26 Feb 2010

EVA trial: MRI is more accurate for early diagnosis of breast cancer than digital mammography

Do we need a revision of current recommendations for breast cancer screening? According to a recent prospective multicenter cohort study published in the "Journal of Clinical Oncology", this appears advisable at least for young women carrying an increased risk of breast cancer. The results of the EVA trial confirm once more that magnetic resonance imaging (MRI) is substantially more accurate for early diagnosis of breast cancer than digital mammography or breast ultrasound: MRI is three times more sensitive for breast cancer than digital mammography.

26 Feb 2010

Accelerated radiation therapy helps reduce amount of chemotherapy in advanced head and neck cancer patients

Using an accelerated, shorter course of radiation therapy for patients with advanced head and neck cancer allows doctors to reduce the amount of chemotherapy, thus reducing toxicity, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

26 Feb 2010

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avastin.

25 Feb 2010

Presence of SIBLING proteins in premalignant oral lesions may predict oral cancer

The presence of certain proteins in premalignant oral lesions may predict oral cancer development, Medical College of Georgia researchers said.

24 Feb 2010

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.

23 Feb 2010

Head and neck tumors in close proximity to sensitive areas may lead to brain injury, visionary risk or hearing loss

When head and neck tumors - from sinus tumors to acoustic neuromas attached to the hearing and balance nerve at the base of the skull - are located in close proximity to such sensitive areas such as the brain and eyes, they are particularly dangerous due to possible brain injury, visionary risk or hearing loss.

23 Feb 2010

Carcinoma News and Research

Further Reading

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

Positive data from Argos Therapeutics' AGS-003 Phase 2 trial for mRCC

Men employed in occupations with potential exposure to sunlight have reduced risk of kidney cancer

Liver transplantation specialists form guidelines for allocation of organs for patients with HCC

OSCC cells express VEGFR1, VEGFR2 and serve as targets and effectors for VEGF: Study

bioTheranostics launches CancerTYPE ID database and KRAS mutational testing

Study shows link between Vitamin D levels and basal cell carcinoma

PINC trial to test anti-malarial drug in women with DCIS

ArQule reports net loss of $36,136,000 for 2009

Celsion to commence Phase II Study of ThermoDox and RFA for CRLM

SUVmax in head and neck squamous cell carcinoma patients predict overall survival

Study shows ghrelin prevents acute liver damage, reduces oxidative stress and inflammation

Widely used biomarkers in early detection of liver cancer are not ideal: Study

Combining DCP and AFP biomarkers may improve early detection of liver cancer

EVA trial: MRI is more accurate for early diagnosis of breast cancer than digital mammography

Accelerated radiation therapy helps reduce amount of chemotherapy in advanced head and neck cancer patients

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

Presence of SIBLING proteins in premalignant oral lesions may predict oral cancer

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Head and neck tumors in close proximity to sensitive areas may lead to brain injury, visionary risk or hearing loss

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News